| |
Hemizygous loss 18q21.32-q22.3†
|
Single copy gain 13q11-q12.3‡
|
CNN LOH 13q21.31-qter§
|
|---|
|
Tumor (%)*
|
Expected mBAF
|
Observed mBAF
|
Tumor (%)
|
Expected mBAF
|
Observed mBAF
|
Tumor (%)
|
Expected mBAF
|
Observed mBAF
|
Tumor (%)
|
|---|
|
0
|
0.5
|
0.53
|
12
|
0.5
|
0.53
|
15
|
0.5
|
0.53
|
6
|
|
10 (7-12)
|
0.53
|
0.53
|
11
|
0.52
|
0.53
|
12
|
0.55
|
0.54
|
7
|
|
14 (10-17)
|
0.54
|
0.53
|
12
|
0.53
|
0.53
|
12
|
0.57
|
0.55
|
9
|
|
21 (17-26)
|
0.56
|
0.55
|
18
|
0.55
|
0.54
|
16
|
0.6
|
0.58
|
16
|
|
23 (18-28)
|
0.56
|
0.6
|
32
|
0.55
|
0.56
|
28
|
0.62
|
0.64
|
28
|
|
30 (24-35)
|
0.59
|
0.58
|
27
|
0.57
|
0.55
|
21
|
0.65
|
0.62
|
24
|
|
34 (28-40)
|
0.60
|
0.59
|
31
|
0.57
|
0.55
|
23
|
0.67
|
0.64
|
29
|
|
45 (38-51)
|
0.65
|
0.61
|
37
|
0.59
|
0.56
|
27
|
0.72
|
0.67
|
33
|
|
47 (40-54)
|
0.65
|
0.65
|
46
|
0.6
|
0.57
|
35
|
0.74
|
0.71
|
42
|
|
50 (43-57)
|
0.67
|
0.64
|
43
|
0.6
|
0.57
|
30
|
0.75
|
0.7
|
39
|
|
79 (74-83)
|
0.83
|
0.84
|
81
|
0.64
|
0.6
|
51
|
0.9
|
0.89
|
77
|
|
100
|
1
|
0.93
|
93
|
0.67
|
0.65
|
88
|
1
|
0.95
|
89
|
- *95% confidence interval within parentheses. †Hemizygous loss chr18:54400001-71300000. ‡Single copy gain chr13:16000001-31100000. §Copy number neutral LOH chr13:60500001-114142980.
